Drug intelligence / Profile preview

3H-10000

Development stage: Phase 2
Lead developer: 3H (Shanghai) Pharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

3H-10000 is an antibody-drug conjugate (ADC) targeting fibroblast growth factor receptor 2b (FGFR2b), currently under development by 3H Pharmaceuticals (思康睿奇) for the treatment of advanced solid tumors. FGFR2b is a splice variant of FGFR2 that is frequently overexpressed in various cancers, including gastric and gastroesophageal junction adenocarcinomas. The drug is designed to selectively bind to FGFR2b-expressing tumor cells, internalize, and release a cytotoxic payload to induce cell death. It is currently being evaluated in a Phase I/II first-in-human clinical trial (CTR20254555) in China to assess its safety, tolerability, and preliminary efficacy in patients with unresectable or metastatic advanced solid tumors.

Other names: anti-FGFR2b ADCanti-FGFR-2b ADCanti-FGFR 2b ADC3H-10000 ADC

Targets

FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)

Beyond the preview

Go deeper on 3H-10000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3H-10000.

Explore the full profile